$16.650
-0.579 (-3.48%)At close
NEO News
NEO Events
NeoGenomics Expands Partnership with Indica Labs
NeoGenomics has expanded its partnership with Indica Labs. The collaboration is intended to scale NeoGenomics' digital pathology infrastructure and accelerate AI-driven diagnostics across its enterprise, giving healthcare providers and their patients more timely, consistent access to advanced diagnostic insight. NeoGenomics selected the Indica Labs HALO AP platform to enable its digital pathology operations through a scalable, cloud-based framework. The vendor-neutral image management system is designed to provide a flexible operating model that lets NeoGenomics add third-party or in-house-developed AI tools while limiting integration costs. This new infrastructure is intended to streamline operations and give customers direct access to advanced digital capabilities without the burden of heavy capital investment, complex IT integration, or change management. As the antibody-drug conjugate pipeline across oncology grows, this will position NeoGenomics to be ready with testing capabilities as AI-based biomarker applications emerge. The company also expects the infrastructure to support future work in AI co-development and clinical trial collaborations, while adding to its large-scale, curated pathology datasets.
Nasdaq Hits Record Highs, S&P 500 Up 0.7%
Broad-based strength in the mega-cap tech space - in spite of continued upward pressure in Treasury yields - helped the Nasdaq Composite to fresh record highs on Monday and also lifted S&P 500 by 0.7%. Among the Mag-7, Nvidia, Metaand Teslawere up by about 2%. Computer Hardware stocks like Seagateand Western Digitalwere also notably higher, rising 4% and 6%, respectively. Rate sensitive sectors lagged, with Real Estate and Utilities finishing the day as the two worst performing areas of the market as the yield on the 10-year benchmark closed at the highs and above 5.3% for the first time since 2002.In the opening hour of the evening session, S&P e-minis and Nasdaq 100 contracts are up by about a decimal. WTI Crude Oil is down for the third straight session to trade below $90 per barrel as more constructive reports of traffic navigating the Strait of Hormuz and reports of a G7 supply release supercede the absence of a U.S.-Iran resolution.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Option Care Healthup 21.0% after FT report company is under takeover interest from McKesson and PE partnerFreshworksup 4.3% after admission into S&P SmallCap 600 indexLeonardo DRSup 1.8% after completing training, delivery for INOD Block III to Australian ArmyXenon Pharmaceuticalsup 1.7% after being started with Buy at GuggenheimORIC Pharmaceuticalsup 1.5% after entering pact with Cancer Research UK to advance ORIC-259Pinterestup 1.0% after naming new CFOLOWER -NeoGenomicsdown 3.1% after Q3 pre-announcement, CEO transitionTORM plcdown 1.4% after equity offering
NeoGenomics Shares Down 2% at $18.73 After Q3 Pre-Announcement
NeoGenomics down 2% at $18.73 after Q3 pre-announcement, CEO transition
NeoGenomics Expects Q3 Revenue of Approximately $209 Million
The company states: "Although NeoGenomics has not finalized its financial results as of and for the quarter ended September 30, 2026, NeoGenomics expects to report third quarter total revenue of approximately $209 million, including year-over-year next-generation sequencing (NGS) revenue growth of approximately 28%. The Company is also reiterating its full year total revenue and adjusted EBITDA guidance as provided on July 28, 2026."
NeoGenomics Appoints Warren Stone as CEO
The company states: "NeoGenomics announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief Executive Officer (CEO) and a member of the Board, effective January 4, 2027. Tony Zook, the Company's current CEO and a member of the Board, will assume the role of Executive Chair at that time and will continue to work in close alignment with Mr. Stone and the Board. In conjunction with Mr. Zook being named Executive Chair, long-time Chair of the Board, Lynn Tetrault, will continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, at which point she does not intend to stand for reelection. The Board appointed Michael Kelly, a current independent Board member since 2020, as the new Lead Independent Director effective January 4, 2027."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.








